Texas Peptide Laws 2024: What Residents and Businesses Need to Know About BPC-157, TB-500, and Compounded Peptide Therapies
As interest in peptide therapies such as BPC-157 and TB-500 continues to grow among Texas consumers, wellness clinics, and compounding pharmacies, questions about the state's regulatory posture have intensified. Unlike several other states that have moved to explicitly restrict or clarify the legal status of specific peptides, Texas has not enacted a peptide-specific statute. Instead, access and enforcement in Texas are shaped by a combination of the Texas Controlled Substances Act, Texas State Board of Pharmacy compounding rules, Texas Medical Board policy on prescribing practices, and overlapping federal action from the FDA. This update, drawing on the analysis compiled at Peptide Laws' Texas regulatory guide, outlines where things currently stand.
What Happened
There is no dedicated Texas statute naming BPC-157, TB-500, or similar research peptides as controlled substances. Texas has not scheduled these compounds under the Texas Controlled Substances Act, which largely tracks the federal Controlled Substances Act but allows the state, through the Texas Department of Public Safety and the Texas Health and Human Services Commission, to add substances independently. To date, that independent scheduling authority has not been exercised for BPC-157 or TB-500.
Instead, regulatory pressure on peptide availability in Texas flows primarily from two channels: the FDA's determination regarding bulk drug substances eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, and the Texas State Board of Pharmacy's enforcement of compounding standards consistent with that federal framework. The FDA's Pharmacy Compounding Advisory Committee has previously reviewed BPC-157 and flagged safety concerns—including potential tumorigenicity and immunogenicity risks—that influence whether compounding pharmacies nationwide, including those licensed in Texas, may legally prepare it for patients.
State Context
Texas has a long regulatory history of aligning closely with FDA compounding standards while granting the Texas Medical Board substantial discretion over physician prescribing practices, including off-label use. The Texas Medical Board has not issued a peptide-specific rule or formal position statement dedicated to BPC-157 or TB-500. Physicians operating anti-aging, longevity, or sports-medicine clinics in Texas generally prescribe peptides under the broader authority granted to licensed practitioners, provided such prescriptions meet standard-of-care documentation requirements and are not derived from substances the FDA has deemed ineligible for compounding.
Federal Comparison
At the federal level, BPC-157 and TB-500 remain unapproved for any human therapeutic indication and are not classified as controlled substances under the federal Controlled Substances Act. However, the FDA's bulk substances determinations under 503A—and related enforcement against 503B outsourcing facilities—have a more direct practical effect on legal access than scheduling would. Texas has not diverged from this federal approach; the state's pharmacy board defers to FDA determinations regarding which bulk substances compounders may legally use. This creates a regulatory environment where the controlling question in Texas is less "Is this peptide illegal?" and more "Is this peptide currently eligible for compounding under federal rules?"
Impact on Stakeholders
For Texas consumers, this means peptides like BPC-157 may be available through some compounding pharmacies or clinics but subject to shifting federal eligibility determinations that can change access with little state-level notice. For telemedicine providers—an increasingly common channel for peptide prescriptions—Texas's telemedicine statutes require an established practitioner-patient relationship and appropriate documentation, but do not impose peptide-specific telehealth restrictions. Compounding pharmacies and 503B outsourcing facilities operating in Texas face the most direct compliance exposure, as FDA bulk substance rulings can render previously compounded peptides non-compliant virtually overnight.
Key Dates and Next Steps
No Texas legislative session has yet produced a peptide-specific bill signed into law as of this writing, and the 89th Texas Legislature's next regular session would be the most likely venue for such action. Stakeholders should monitor FDA bulk drug substance category updates, Texas State Board of Pharmacy rule postings, and Texas Medical Board guidance, as these remain the primary levers affecting legal peptide access in the state. This overview reflects the regulatory landscape as understood at publication and is subject to change; readers should consult the full guide at Peptide Laws and verify current rules directly with the relevant Texas agencies before making compliance decisions. This article is intended for informational purposes and does not constitute legal advice.
Source: This article was informed by research from Peptidelaws.
Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. Regulations and enforcement may change. Consult qualified professionals for guidance specific to your situation.